FDA panel urges approval of once-weekly semaglutide in type 2 diabetes

A medical advisory panel of the US FDA has voted 16-0 in favor of approving Danish diabetes specialist Novo Nordisk’s once-weekly semaglutide.

Novo submitted for approval to market the medicine to adults with type 2 diabetes in December last year.

The recommendation was based on data from the SUSTAIN Phase III trial program, which included a cardiovascular outcomes trial.

Semaglutide is currently under review by several regulatory agencies, including in Europe and Japan.